• Luminescent ATP Cell Viability Assay Kit I: Ferroptosis

  2026-08-07

  Translate ferroptosis experiments into rapid, quantitative viability data with an ATP-proximal luminescent readout. The ready-to-use format supports sensitive cytotoxicity, proliferation, and metabolic studies while reducing the handling burden of conventional colorimetric assays.

• ER Stress-Induced Prometastatic States in Tumor Cell Surviva

  2026-08-07

  Conod et al. (2022) uncover how surviving impending cell death via ER stress triggers the emergence of prometastatic tumor cells (PAMEs) with enhanced metastatic potential. This work clarifies the molecular and cellular mechanisms underlying metastatic origin, with implications for apoptosis research and therapeutic targeting.

• Filipin III: Precision Cholesterol Detection in Membranes

  2026-08-06

  Filipin III, a polyene macrolide antibiotic, offers unmatched specificity for cholesterol detection in biological membranes, revolutionizing workflows in cell biology and immunometabolism. This guide decodes the product’s mechanism, optimal protocols, and troubleshooting strategies, empowering researchers to visualize membrane cholesterol with clarity and confidence.

• CCK-8 Cell Proliferation Assay: Enhanced Protocols & Insight

  2026-08-06

  Cell Counting Kit-8 (CCK-8) delivers rapid, sensitive cell viability and proliferation data with streamlined workflows. This guide translates recent advances from biomaterials research into actionable assay optimization, troubleshooting, and high-impact use-cases for cancer, tissue engineering, and biomaterial evaluation.

• Bufuralol Hydrochloride in hiPSC-Organoid Cardiovascular Stu

  2026-08-05

  Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, is propelling next-generation cardiovascular pharmacology through advanced hiPSC-derived organoid models. This article details actionable workflow strategies, protocol parameters, and troubleshooting insights to maximize translational research impact with APExBIO’s high-purity compound.

• Caveolin-1 Regulates Cholesterol Homeostasis in MASLD Progre

  2026-08-05

  This study establishes Caveolin-1 as a central regulator of hepatic cholesterol homeostasis during metabolic dysfunction-associated steatotic liver disease (MASLD). By dissecting mechanisms linking cholesterol accumulation, ER stress, and pyroptosis, the research clarifies how Caveolin-1 deficiency exacerbates disease progression and identifies molecular targets for intervention.

• Distinct Cell Death Pathways in ALL Revealed by Microtubule

  2026-08-04

  This study demonstrates that primary acute lymphoblastic leukemia (ALL) cells respond to microtubule destabilization with phase-specific cell death mechanisms, revealing both canonical and non-canonical pathways. The findings refine our understanding of how microtubule targeting agents (MTAs) exert anti-leukemic effects beyond mitosis, with implications for optimizing chemotherapeutic strategies and for research on cell death modulation.

• Nutlin-3a: Benchmark MDM2 Inhibitor for p53 Pathway Activati

  2026-08-04

  Nutlin-3a is a potent small-molecule MDM2 inhibitor that stabilizes p53, resulting in cell cycle arrest and apoptosis induction in diverse cancer models. Quantitative data support its efficacy in both wild-type and mutant p53 contexts, making it a critical tool for cancer research targeting the p53 pathway.

• Ac-YVAD-CMK in Kupffer Cells: Redefining Liver Inflammation

  2026-08-03

  Explore how Ac-YVAD-CMK, a selective caspase-1 inhibitor, uncovers new layers of inflammatory and pyroptosis regulation in liver Kupffer cells. This article provides a distinct mechanistic perspective and practical guidance for advanced anti-inflammatory research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-08-03

  This study systematically characterizes how the pathological state of metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of three major Corydalis saxicola Bunting total alkaloids. The findings reveal disease-driven modulation of drug metabolizing enzymes and transporters, with implications for rational dosing in MASH therapy.

• Evaluating pH-Dependent Drug Interactions in HER2+ Cancer Th

  2026-08-02

  This article analyzes a recent study assessing whether acid-reducing agents affect the solubility and absorption of ribociclib, a CDK4/6 inhibitor used in HER2-positive metastatic breast cancer. Using a Quality by Design (QbD) approach, the authors demonstrate that physiologically relevant pH shifts do not significantly impair ribociclib’s absorption, providing a robust methodology for early-stage evaluation of drug–drug interactions.

• Birinapant (TL32711): Applied Apoptosis Induction in Cancer

  2026-08-01

  Birinapant (TL32711) from APExBIO is an elite SMAC mimetic enabling precise, reproducible induction of apoptosis in cancer research. This guide synthesizes stepwise workflow enhancements, practical troubleshooting, and new biomarker-driven strategies to maximize data quality in apoptosis and chemoradiotherapy resistance studies.

• Rimonabant (SR141716): Beyond Appetite—CB1 Antagonism in Neu

  2026-07-31

  Explore how Rimonabant (SR141716) advances endocannabinoid system research as a potent CB1 antagonist. This article uncovers novel neurobiological and anti-inflammatory applications, offering insights distinct from standard obesity models.

• Flavopiridol (L868275): CDK Inhibition, ER Stress, and New F

  2026-07-31

  Explore how Flavopiridol, a potent pan-CDK inhibitor, uniquely bridges cell cycle arrest and endoplasmic reticulum stress pathways. This article reveals new assay strategies and practical insights for advanced cancer research, setting it apart from standard protocol guides.

• RWJ 67657 (SKU C5316): Precision p38α/β Inhibition for Relia

  2026-07-30

  This article examines how RWJ 67657 (SKU C5316) addresses critical laboratory challenges in cell viability and cytokine modulation assays. Drawing from new mechanistic evidence and practical optimization insights, we detail its specific advantages in selectivity, reproducibility, and workflow integration. APExBIO’s RWJ 67657 emerges as a best-in-class tool for researchers studying inflammatory disease models.

16334 records 1/1089 page Next 12345 下5页 Last page